A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics
Ricardo Sánchez(Research Institute Hospital 12 de Octubre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Santiago Mercadal(Huntsman Cancer Institute), Marta Cervera(Hospital Universitari Joan XXIII de Tarragona), Rodrigo de Nicolás(Hospital Universitario 12 De Octubre), Mireia Morgades(Josep Carreras Leukaemia Research Institute), Rosa Coll(Hospital Universitari de Girona Doctor Josep Trueta), Esther Onecha(Hospital Universitario 12 De Octubre), Yanira Ruiz‐Heredia(Hospital Universitario 12 De Octubre), Rosa Ayala(Hospital Universitario 12 De Octubre), Josep‐María Ribera(Universitat Autònoma de Barcelona), Lurdes Zamora(Universitat Autònoma de Barcelona), Susana Vives, Jordi Ribera(Josep Carreras Leukaemia Research Institute), José María Sánchez‐Pina(Research Institute Hospital 12 de Octubre), Olga García(Institut Català d'Oncologia), Alexandra Juárez-Rufián(Hospital Universitario 12 De Octubre)
Cited by 23
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523